Holen Sie sich die Stockscreener-App
1.96
10.09%
-0.22
Handel nachbörslich:
1.96
Schlusskurs vom Vortag:
$2.18
Offen:
$2.12
24-Stunden-Volumen:
52,637
Relative Volume:
0.47
Marktkapitalisierung:
$10.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-18.33%
1M Leistung:
-17.99%
6M Leistung:
-64.59%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.90
$2.1639
1-Wochen-Bereich:
$1.90
$2.6918
52-Wochen-Spanne:
$1.90
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Vergleichen Sie TRAW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.96 | 10.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost - Investing.com
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 - MSN
Traws Pharma Reports 2024 Financial Results and CEO Change - TipRanks
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports Full Year 2024 Results and Business Highlights - GlobeNewswire
Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday - Defense World
Traws Pharma Announces CEO Transition as Werner Cautreels Retires - MSN
Traws Pharma announces CEO retirement and interim successor By Investing.com - Investing.com South Africa
Traws Pharma announces CEO retirement and interim successor - Investing.com India
Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis - MarketScreener
Traws Pharma Announces Management Updates - GlobeNewswire
Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue - Stock Titan
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment - MSN
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma to Host Investor Event on Bird Flu and COVID - GlobeNewswire
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - Yahoo Finance
Former CDC Director Unveils Game-Changing Bird Flu and COVID Treatments at Traws Pharma Event - Stock Titan
Traws Pharma presents data on COVID-19 candidate ratutrelvir at ICAR - TipRanks
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment By Investing.com - Investing.com South Africa
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment - Investing.com
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewswire
Breakthrough: Next-Gen COVID Drug Defeats 18 Variants Without Ritonavir Boost - Stock Titan
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates - GlobeNewswire
Breakthrough: New Bird Flu Drug Achieves Remarkable 99.9% Viral Reduction in Latest Primate Tests - Stock Titan
Traws Pharma Unveils Promising Bird Flu Treatment Data - MyChesCo
Traws Pharma touts bird flu drug efficacy at ICAR By Investing.com - Investing.com South Africa
Traws Pharma touts bird flu drug efficacy at ICAR - Investing.com
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - The Manila Times
Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR -March 21, 2025 at 07:03 am EDT - Marketscreener.com
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewswire
Breakthrough: Revolutionary Bird Flu Drug Achieves Perfect Survival Rate in Latest Trial Data - StockTitan
Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP Securities -March 10, 2025 at 05:35 pm EDT - Marketscreener.com
Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment - MSN
PA-based biopharma company reports positive results testing efficacy of bird flu antiviral - Pennsylvania Business Report
TRAW stock touches 52-week low at $2.14 amid sharp annual decline - Investing.com
Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update - Defense World
Traws Pharma reports promising bird flu treatment results By Investing.com - Investing.com Canada
Traws Pharma reports promising bird flu treatment results - Investing.com India
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewswire
Can Traws Pharma's Single-Dose Treatment Combat the Growing Bird Flu Threat? - StockTitan
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Es liegen keine Finanzdaten für Traws Pharma Inc (TRAW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):